← back to search

Klaus-Henning Kahl

Technical University of Munich · DE
Area of research
Pulmonary and Respiratory Medicine · Genetics
Research interest
Research interests include Medicine, Radiation therapy, Radiosurgery, Internal medicine, Stereotactic radiotherapy, and Multivariate analysis.
h-index
citations
750
works
15
NIH funding
primary concept
email

Recent publications

Dummy run for planning of isotoxic dose-escalated radiation therapy for glioblastoma used in the PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06)
Clinical and Translational Radiation Oncology 2024cited by 2position: middledoi
Opportunities and Alternatives of Modern Radiation Oncology and Surgery for the Management of Resectable Brain Metastases
Cancers 2023cited by 11position: middledoi
Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis
International Journal of Cancer 2021cited by 35position: middledoi
Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the ‘TOaSTT’ database
Radiation Oncology 2021cited by 30position: middledoi
Continued versus Interrupted Targeted Therapy during Metastasis-Directed Stereotactic Radiotherapy: A Retrospective Multi-Center Safety and Efficacy Analysis
Cancers 2021cited by 22position: middledoi
Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy
Radiation Oncology 2020cited by 16position: middledoi
Correction to: Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy
Radiation Oncology 2020cited by 4position: middledoi
The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases
BMC Cancer 2019cited by 96position: middledoi
Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT
Clinical Lung Cancer 2019cited by 45position: middledoi
Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy
Radiotherapy and Oncology 2018cited by 45position: middledoi
Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease
Radiotherapy and Oncology 2017cited by 61position: middledoi
Stereotactic body radiotherapy (SBRT) for pulmonary metastases from renal cell carcinoma—a multicenter analysis of the German working group “Stereotactic Radiotherapy”
Journal of Thoracic Disease 2017cited by 51position: middledoi
Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases—A pooled analysis of the German working group “stereotactic radiotherapy”
Lung Cancer 2016cited by 160position: middledoi
Influence of Institutional Experience and Technological Advances on Outcome of Stereotactic Body Radiation Therapy for Oligometastatic Lung Disease
International Journal of Radiation Oncology*Biology*Physics 2016cited by 47position: middledoi
Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy
Radiotherapy and Oncology 2015cited by 125position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Matthias Gückenberger · Stadtspital Waid6 papers (2017–2021)Fabian Lohaus · German Cancer Research Center6 papers (2017–2021)Oliver Blanck · Friedrich-Alexander-Universität Erlangen-Nürnberg6 papers (2017–2021)Sonja Adebahr · Heidelberg University5 papers (2018–2021)Jana Schaule · Friedrich-Alexander-Universität Erlangen-Nürnberg4 papers (2020–2021)Markus Schymalla · University Hospital Frankfurt4 papers (2020–2021)Stephanie Kroeze · Kantonsspital Aarau4 papers (2020–2021) · 4 papers (2020–2021)Michael Geier · Technical University of Munich4 papers (2020–2021)David Kaul · University of Potsdam4 papers (2020–2021) · 3 papers (2020–2021)Daniel Buergy · Heidelberg University3 papers (2020–2021)An Claes · Utrecht University3 papers (2020–2021)Stephanie E. Combs · Brooke Army Medical Center3 papers (2020–2021)Susanne Stera · University Hospital Frankfurt3 papers (2020–2021)Franziska Eckert · Comprehensive Cancer Center Vienna3 papers (2020–2021)Guido Henke · Johannes Gutenberg University Mainz3 papers (2020–2021) · 3 papers (2020–2021)Falk Roeder · Paracelsus Medical University3 papers (2020–2021)Marciana Nona Duma · Technical University of Munich2 papers (2017–2018)